

Doug Coyle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8852678/publications.pdf>

Version: 2024-02-01

135
papers

4,253
citations

136950
32
h-index

128289
60
g-index

139
all docs

139
docs citations

139
times ranked

6181
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Lancet</i> , The, 2015, 386, 258-265.	13.7	487
2	Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. <i>The Cochrane Library</i> , 2008, , CD001155.	2.8	260
3	Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. <i>The Cochrane Library</i> , 2008, , CD003376.	2.8	237
4	Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. <i>Headache</i> , 2015, 55, 221-235.	3.9	197
5	A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL. <i>Systematic Reviews</i> , 2014, 3, 110.	5.3	172
6	Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. <i>The Cochrane Library</i> , 2008, , CD004523.	2.8	169
7	Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation. <i>Value in Health</i> , 2013, 16, 498-506.	0.3	127
8	Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1122.	7.4	126
9	Global Estimate of Lung Cancer Mortality Attributable to Residential Radon. <i>Environmental Health Perspectives</i> , 2018, 126, 057009.	6.0	101
10	Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. <i>Systematic Reviews</i> , 2015, 4, 147.	5.3	99
11	Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. <i>BMJ Open</i> , 2014, 4, e004301-e004301.	1.9	93
12	Parents'™ Needs Following Identification of Childhood Hearing Loss. <i>American Journal of Audiology</i> , 2008, 17, 38-49.	1.2	88
13	Effects of aerobic exercise, resistance exercise or both, on patient-reported health status and well-being in type 2 diabetes mellitus: a randomised trial. <i>Diabetologia</i> , 2010, 53, 632-640.	6.3	84
14	A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. <i>Journal of Cancer Survivorship</i> , 2015, 9, 683-691.	2.9	80
15	Cannabis-based products for pediatric epilepsy: A systematic review. <i>Epilepsia</i> , 2019, 60, 6-19.	5.1	79
16	Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. <i>BMJ: British Medical Journal</i> , 2018, 362, k3478.	2.3	69
17	The Influence of Experiential Knowledge on Prenatal Screening and Testing Decisions. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, 12, 115-124.	1.7	64
18	Opportunity Cost of Funding Drugs for Rare Diseases. <i>Medical Decision Making</i> , 2014, 34, 1016-1029.	2.4	53

#	ARTICLE	IF	CITATIONS
19	Auditory and language outcomes in children with unilateral hearing loss. <i>Hearing Research</i> , 2019, 372, 42-51.	2.0	51
20	Parentsâ€™ perspectives on the impact of the early diagnosis of childhood hearing loss. <i>International Journal of Audiology</i> , 2007, 46, 97-106.	1.7	49
21	Children With Mild Bilateral and Unilateral Hearing Loss: Parentsâ€™ Reflections on Experiences and Outcomes: Table 1.. <i>Journal of Deaf Studies and Deaf Education</i> , 2016, 21, 34-43.	1.2	49
22	Statistical Analysis in Pharmacoeconomic Studies. <i>Pharmacoeconomics</i> , 1996, 9, 506-516.	3.3	48
23	Sepsis-Associated Mortality, Resource Use, and Healthcare Costs: A Propensity-Matched Cohort Study*. <i>Critical Care Medicine</i> , 2021, 49, 215-227.	0.9	45
24	An Evaluation Framework for Funding Drugs for Rare Diseases. <i>Value in Health</i> , 2012, 15, 982-986.	0.3	40
25	Cost Effectiveness of Epoetin-?? to Augment Preoperative Autologous Blood Donation in Elective Cardiac Surgery. <i>Pharmacoeconomics</i> , 2000, 18, 161-171.	3.3	38
26	Estimating the expected value of partial perfect information: a review of methods. <i>European Journal of Health Economics</i> , 2008, 9, 251-259.	2.8	38
27	Experiences of caregivers of children with inherited metabolic diseases: a qualitative study. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 168.	2.7	38
28	The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 12.	2.7	38
29	Cost Effectiveness of Nasal Calcitonin in Postmenopausal Women. <i>Pharmacoeconomics</i> , 2001, 19, 565-575.	3.3	37
30	Hand assisted laparoscopic surgery versus conventional laparoscopy for colorectal surgery. <i>The Cochrane Library</i> , 2010, , CD006585.	2.8	37
31	A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer. <i>PLoS ONE</i> , 2014, 9, e108749.	2.5	37
32	Cost Effectiveness of a Survivorship Care Plan for Breast Cancer Survivors. <i>Journal of Oncology Practice</i> , 2014, 10, e86-e92.	2.5	36
33	Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1463-1473.	1.6	32
34	EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control. <i>BMJ Open</i> , 2014, 4, e006945.	1.9	29
35	Cost Effectiveness of Infant Vaccination for Rotavirus in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2012, 23, 71-77.	1.9	28
36	Transient elastography for the diagnosis of liver fibrosis: a systematic review of economic evaluations. <i>Liver International</i> , 2017, 37, 851-861.	3.9	28

#	ARTICLE	IF	CITATIONS
37	ANALYZING DIFFERENCES IN THE COSTS OF TREATMENT ACROSS CENTERS WITHIN ECONOMIC EVALUATIONS. International Journal of Technology Assessment in Health Care, 2001, 17, 155-163.	0.5	27
38	Effect of Folic Acid Supplementation in Pregnancy on Preeclampsia: The Folic Acid Clinical Trial Study. Journal of Pregnancy, 2013, 2013, 1-9.	2.4	27
39	Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy. JACC: Clinical Electrophysiology, 2018, 4, 660-668.	3.2	27
40	Child and family experiences with inborn errors of metabolism: a qualitative interview study with representatives of patient groups. Journal of Inherited Metabolic Disease, 2016, 39, 139-147.	3.6	26
41	Costs associated with infant bronchiolitis in the Baffin region of Nunavut. International Journal of Circumpolar Health, 2005, 64, 38-45.	1.2	25
42	Costs of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer or carcinoma of the bronchus. Clinical Oncology, 1997, 9, 313-321.	1.4	24
43	Cannabis-based products for pediatric epilepsy: An updated systematic review. Seizure: the Journal of the British Epilepsy Association, 2020, 75, 18-22.	2.0	24
44	COST-EFFECTIVENESS OF EXERCISE PROGRAMS IN TYPE 2 DIABETES. International Journal of Technology Assessment in Health Care, 2012, 28, 228-234.	0.5	23
45	The Health System Costs of Potentially Inappropriate Prescribing: A Population-Based, Retrospective Cohort Study Using Linked Health Administrative Databases in Ontario, Canada. PharmacoEconomics - Open, 2020, 4, 27-36.	1.8	22
46	Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation (TRIST Study): A Randomized Controlled Trial Evaluating 2 Red Cell Transfusion Thresholds. Blood, 2016, 128, 1032-1032.	1.4	22
47	Cost Analysis of Universal Screening vs. Risk Factor-Based Screening for Methicillin-Resistant Staphylococcus aureus (MRSA). PLoS ONE, 2016, 11, e0159667.	2.5	22
48	Toward a Functional Definition of a "Rare Disease" for Regulatory Authorities and Funding Agencies. Value in Health, 2014, 17, 757-761.	0.3	21
49	A review of economic evaluation in osteoporosis. Arthritis and Rheumatism, 1999, 12, 425-434.	6.7	20
50	Estimates of effectiveness and reach for "return on investment" modelling of smoking cessation interventions using data from England. Addiction, 2018, 113, 19-31.	3.3	20
51	Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation. Addiction, 2018, 113, 7-18.	3.3	20
52	Implanted spinal neuromodulation interventions for chronic pain in adults. The Cochrane Library, 2022, 2022, CD013756.	2.8	20
53	The psychometric properties of patient preferences in osteoporosis. Journal of Rheumatology, 2001, 28, 132-7.	2.0	20
54	Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD. Addiction, 2018, 113, 65-75.	3.3	19

#	ARTICLE	IF	CITATIONS
55	Cost-Effectiveness of Hair Apposition Technique Compared With Standard Suturing in Scalp Lacerations. <i>Annals of Emergency Medicine</i> , 2005, 46, 237-242.	0.6	18
56	Application of a Policy Framework for the Public Funding of Drugs for Rare Diseases. <i>Journal of General Internal Medicine</i> , 2014, 29, 774-779.	2.6	18
57	Effectiveness of Outpatient Versus Operating Room Hysteroscopy for the Diagnosis and Treatment of Uterine Conditions: A Systematic Review and Meta-Analysis. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 930-941.	0.7	17
58	Transradial Versus Transfemoral Access for Percutaneous Coronary Intervention in ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009994.	3.9	17
59	Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. <i>Value in Health</i> , 2017, 20, 586-592.	0.3	16
60	Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis. <i>Pharmacoeconomics</i> , 2018, 36, 1253-1261.	3.3	16
61	Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 104.	2.7	16
62	Core Outcome Sets for Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Phenylketonuria. <i>Pediatrics</i> , 2021, 148, .	2.1	16
63	Is it costâ€Eeffective to provide internetâ€Ebased interventions to complement the current provision of smoking cessation services in the Netherlands? An analysis based on the EQUIPTMOD. <i>Addiction</i> , 2018, 113, 87-95.	3.3	15
64	Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 12.	2.7	15
65	Cannabis for pediatric epilepsy: protocol for a living systematic review. <i>Systematic Reviews</i> , 2018, 7, 95.	5.3	14
66	Value of information analysis for a new technology: Computer-assisted total knee replacement. <i>International Journal of Technology Assessment in Health Care</i> , 2007, 23, 337-342.	0.5	13
67	What Guidance are Economists Given on How to Present Economic Evaluations for Policymakers? A Systematic Review. <i>Value in Health</i> , 2015, 18, 915-924.	0.3	12
68	Neurologistsâ€™ perspectives on medical cannabis for pediatric drug-resistant epilepsy in Canada: A qualitative interview study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 78, 118-126.	2.0	12
69	Reducing Periconceptional Methylmercury Exposure: Costâ€EUtility Analysis for a Proposed Screening Program for Women Planning a Pregnancy in Ontario, Canada. <i>Environmental Health Perspectives</i> , 2015, 123, 1337-1344.	6.0	11
70	Parent Report of Amplification Use in Children with Mild Bilateral or Unilateral Hearing Loss. <i>Journal of the American Academy of Audiology</i> , 2019, 30, 093-102.	0.7	11
71	Barriers in accessing medical cannabis for children with drug-resistant epilepsy in Canada: A qualitative study. <i>Epilepsy and Behavior</i> , 2020, 111, 107120.	1.7	11
72	Internet-Based Implementation of Non-Pharmacological Interventions of the "People Getting a Grip on Arthritis" Educational Program: An International Online Knowledge Translation Randomized Controlled Trial Design Protocol. <i>JMIR Research Protocols</i> , 2015, 4, e19.	1.0	11

#	ARTICLE	IF	CITATIONS
73	Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations. <i>Pharmacoeconomics</i> , 2019, 37, 1261-1276.	3.3	10
74	Cost-Effectiveness of Pharmacological Treatments for Osteoporosis Consistent with the Revised Economic Evaluation Guidelines for Canada. <i>MDM Policy and Practice</i> , 2019, 4, 238146831881884.	0.9	10
75	Comparison of Alternative Sources of Data on Health Service Encounters. <i>Journal of Health Services Research and Policy</i> , 1999, 4, 210-214.	1.7	9
76	The economic evaluation of pharmacotherapies for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2003, 9, 301-307.	2.2	9
77	What Guidance Are Researchers Given on How to Present Network Meta-Analyses to End-Users such as Policymakers and Clinicians? A Systematic Review. <i>PLoS ONE</i> , 2014, 9, e113277.	2.5	9
78	Establishing core outcome sets for phenylketonuria (PKU) and medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency in children: study protocol for systematic reviews and Delphi surveys. <i>Trials</i> , 2017, 18, 603.	1.6	9
79	Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 70.	2.7	9
80	The return of investment of hospital-based surgical quality improvement programs in reducing surgical site infection at a Canadian tertiary-care hospital. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 125-132.	1.8	9
81	Global evidence of gender inequity in academic health research: a living scoping review protocol. <i>JBMEvidence Synthesis</i> , 2020, 18, 2181-2193.	1.3	9
82	Computed tomography coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE-HF 1C). <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1083-1090.	1.2	9
83	Stakeholder perspectives on clinical research related to therapies for rare diseases: therapeutic misconception and the value of research. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 26.	2.7	9
84	Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer. <i>Cmaj</i> , 2021, 193, E1551-E1560.	2.0	9
85	The assessment of the economic return from controlled clinical trials. <i>European Journal of Health Economics</i> , 2003, 4, 6-11.	2.8	8
86	Targeting improved patient outcomes using innovative product listing agreements: a survey of Canadian and international key opinion leaders. <i>ClinicoEconomics and Outcomes Research</i> , 2016, Volume 8, 427-433.	1.9	8
87	A cost effectiveness analysis of interventions to reduce residential radon exposure in Canada. <i>Journal of Environmental Management</i> , 2019, 247, 449-461.	7.8	8
88	Value of mesenchymal stem cell therapy for patients with septic shock: an early health economic evaluation. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 525-532.	0.5	8
89	Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis. <i>Pharmacoeconomics</i> , 2020, 38, 971-980.	3.3	8
90	Nicotine preloading for smoking cessation: the Preloading RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-84.	2.8	8

#	ARTICLE	IF	CITATIONS
91	Assessment of cost-effective changes to the current and potential provision of smoking cessation services: an analysis based on the EQUIPTMOD. <i>Addiction</i> , 2018, 113, 96-105.	3.3	7
92	Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. <i>Systematic Reviews</i> , 2019, 8, 75.	5.3	7
93	Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts. <i>Pharmacoeconomics - Open</i> , 2020, 4, 297-305.	1.8	7
94	Cost-effectiveness of a gestational age metabolic algorithm for preterm and small-for-gestational-age classification. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2021, 3, 100279.	2.6	7
95	Cost-effectiveness of increasing the reach of smoking cessation interventions in Germany: results from the EQUIPTMOD. <i>Addiction</i> , 2018, 113, 52-64.	3.3	6
96	Health Care for Mitochondrial Disorders in Canada: A Survey of Physicians. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 717-726.	0.5	6
97	A technique for approximating transition rates from published survival analyses. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 12.	1.5	6
98	The Impact of Risk on Preference Values: Implications for Evaluations of Postmenopausal Osteoporosis Therapy. <i>Value in Health</i> , 2001, 4, 385-391.	0.3	5
99	Determining utility values related to malaria and malaria chemoprophylaxis. <i>Malaria Journal</i> , 2010, 9, 92.	2.3	5
100	A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. <i>Supportive Care in Cancer</i> , 2017, 25, 2505-2513.	2.2	5
101	A utility of model input uncertainty analysis in transferring tobacco control-related economic evidence to countries with scarce resources: results from the EQUIPT study. <i>Addiction</i> , 2018, 113, 42-51.	3.3	5
102	Service Preferences of Parents of Children With Mild Bilateral or Unilateral Hearing Loss: A Conjoint Analysis Study. <i>Ear and Hearing</i> , 2019, 40, 671-679.	2.1	5
103	Comparative efficacy and safety of antihyperglycemic drug classes for patients with type 2 diabetes following failure with metformin monotherapy: A systematic review and network meta-analysis of randomized controlled trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3515.	4.0	5
104	Spinal cord stimulation for chronic pain. <i>Lancet Neurology</i> , The, 2022, 21, 405.	10.2	5
105	Utility gains from reductions in the modifiable burden of lung cancer attributable to residential radon in Canada. <i>Canadian Journal of Public Health</i> , 2018, 109, 598-609.	2.3	4
106	Mitral Valve Clip for Treatment of Mitral Regurgitation: An Evidence-Based Analysis. <i>Ontario Health Technology Assessment Series</i> , 2015, 15, 1-104.	1.8	4
107	Cost-effectiveness research in osteoporosis. <i>Drug Development Research</i> , 2000, 49, 135-140.	2.9	3
108	Reimbursement-Based Economics "What Is It and How Can We Use It to Inform Drug Policy Reform?". <i>Headache</i> , 2015, 55, 236-247.	3.9	3

#	ARTICLE	IF	CITATIONS
109	A General Population Utility Valuation Study for Metastatic Epidural Spinal Cord Compression Health States. <i>Spine</i> , 2019, 44, 943-950.	2.0	3
110	Virtual follow-up and care for patients with cardiac electronic implantable devices: protocol for a systematic review. <i>Systematic Reviews</i> , 2020, 9, 153.	5.3	3
111	When piloting health services interventions, what predicts real world behaviours? A systematic concept mapping review. <i>BMC Medical Research Methodology</i> , 2020, 20, 76.	3.1	3
112	Bendamustine and Rituximab Versus Conventional Chemoimmunotherapy As a Frontline Treatment for Patients with Indolent B-Cell Lymphoma: A Cost-Effectiveness Analysis. <i>Blood</i> , 2016, 128, 1186-1186.	1.4	3
113	A cost-utility analysis of the impact of electronic nicotine delivery systems on health care costs and outcomes in Canada. <i>Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice</i> , 2022, 42, 29-36.	1.1	3
114	Issues of consensus and debate for economic evaluation in rheumatology. <i>Journal of Rheumatology</i> , 2001, 28, 642-7.	2.0	3
115	Patient decisional needs when considering treatment intensification for type 2 diabetes: A qualitative study in China. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108471.	2.8	2
116	An assessment of uncertainty using two different modelling techniques to estimate the cost effectiveness of mitigating radon in existing housing in Canada. <i>Science of the Total Environment</i> , 2020, 724, 138092.	8.0	2
117	A Retrospective Cohort Study Investigating the Impact of Maternal Pre-Pregnancy Body Mass Index on Pediatric Health Service Utilization. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 1267-1273.	0.7	2
118	Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy. <i>BMJ Open</i> , 2021, 11, e046707.	1.9	2
119	Application of Operations Research to Funding Decisions for Treatments with Rare Disease. <i>Profiles in Operations Research</i> , 2013, , 281-294.	0.4	2
120	A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: A comparison of primary care versus specialist care. <i>Journal of Clinical Oncology</i> , 2004, 22, 665-665.	1.6	2
121	Pertussis vaccination in pregnancy in Canada: a cost-utility analysis. <i>CMAJ Open</i> , 2020, 8, E651-E658.	2.4	2
122	Program Evaluation of Hospital-Based Antenatal Home Care for High-Risk Women. <i>Healthcare Quarterly</i> , 2003, 6, 67-73.	0.7	1
123	Back to Bayesian: A strategy to enhance prognostication of metastatic spine disease. <i>International Journal of Clinical Practice</i> , 2019, 73, e13322.	1.7	1
124	Outpatient uterine assessment and treatment unit in patients with abnormal uterine bleeding: an economic modelling study. <i>CMAJ Open</i> , 2020, 8, E810-E818.	2.4	1
125	Who would benefit from average value-based pricing?. <i>Health Economics (United Kingdom)</i> , 2020, 29, 936-937.	1.7	1
126	Family Experiences with Care for Children with Inherited Metabolic Diseases in Canada: A Cross-Sectional Survey. <i>Patient</i> , 2022, 15, 171-185.	2.7	1

#	ARTICLE	IF	CITATIONS
127	Regional cost effectiveness analyses for increasing radon protection strategies in housing in Canada. Journal of Environmental Radioactivity, 2021, 240, 106752.	1.7	1
128	RESOURCE ALLOCATION FOR THE TREATMENT OF RARE DISEASES. Journal of Epidemiology and Community Health, 2013, 67, e2.12-e2.	3.7	0
129	DEVELOPING AND TESTING A TOOL FOR ASSESSING PHARMACOECONOMIC EVALUATIONS. Journal of Epidemiology and Community Health, 2013, 67, e2.8-e2.	3.7	0
130	THE EPIDEMIOLOGY AND HEALTH SYSTEM IMPACT OF MEDIUM-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY AMONG AFFECTED CHILDREN AND THOSE WITH FALSE POSITIVE NEWBORN SCREENING RESULTS IN ONTARIO, CANADA. Journal of Epidemiology and Community Health, 2013, 67, e2.3-e2.	3.7	0
131	Designing economic evaluations to facilitate optimal decisions: the need to avoid bias. ClinicoEconomics and Outcomes Research, 2016, 8, 73.	1.9	0
132	Increasing the methodological quality and relevance of cost effectiveness analysis. Thrombosis Research, 2017, 150, 121-122.	1.7	0
133	P253Short-term versus indefinite anticoagulant therapy for secondary prevention of unprovoked venous thromboembolism: a decision analysis. European Heart Journal, 2018, 39, .	2.2	0
134	The Psychometric Properties of a Self-Administered, Open-Source Module for Valuing Metastatic Epidural Spinal Cord Compression Utilities. PharmacoEconomics - Open, 2019, 3, 197-204.	1.8	0
135	The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases. Pharmacoeconomics, 2021, 39, 479-480.	3.3	0